BRAIN TUMOR BIOREPOSITORY, HISTOPATHOLOGY, AND IMMUNOLOGIC MONITORING

脑肿瘤生物信息库，组织病理学和免疫学监测核心。罗杰·麦克伦登 医学博士，核心领导者 获得适当获取的组织(脑瘤、正常脑和匹配的体细胞)的途径 是NINDS关于原发和转移的专业研究中心成功的基础 CMS自25年前诞生以来的肿瘤。该生物库已成功获得并 从800多个脑瘤个体中分离脑瘤组织和匹配的外周血体细胞 患者净积累超过6,750块胶质瘤组织。《公爵免疫学》 监控组件的这一核心将提供各种标准和内部开发的多色 免疫功能的流式细胞术分析，包括细胞内细胞因子染色和细胞内脱颗粒 项目1中患者的广泛的表型缺陷T细胞群体。数据库 这个核心的组件将存储来自遗传、细胞遗传学、免疫组织化学、组织学和 生物信息库中所有脑肿瘤组织和正常脑组织的诊断分析 并将数据提供给需要这些数据的研究人员，这些数据在项目1、2和3以及IND，Regulatory， 和杜克大学IRB监督下的生物信息学核心。 该核心的具体目标将支持项目1、2和3中描述的临床和临床前研究： 1)提供和维护经临床注释和编目的人脑肿瘤组织生物信息库， 正常人脑组织和来自所有脑肿瘤患者的匹配体细胞进行临床试验 项目1、2和3；存储库有一个Nautilus数据库，该数据库将链接到临床Oracle数据库 项目1、2和3中临床试验的所有患者都将进入；2)保持对科学的访问 800多例脑肿瘤患者标本与方案1、2、3相关问题及对策 配对的体细胞自20世纪80年代初P50赠款开始进入该资料库；3) 提供综合的病理学、组织学、免疫组织化学和分子诊断研究 项目1、2和3，这些项目将输入生物库Nautilus数据库并链接到Oracle 每个患者的临床数据库；4)为登记的患者提供全面的免疫监测 项目1、2和3中的临床试验，使用高度标准化/经过验证的基于最新技术的流式细胞仪 化验。 相关性(请参阅说明)： 脑肿瘤组织的可用性对于确定患者是否符合临床试验的资格是必要的。 大多数新的治疗方法依赖于在每个患者的脑瘤中展示特定的分子。 以便让患者参加适当的临床试验。恶性胶质瘤的疫苗研究需要 疫苗治疗反应的免疫学监测。

Core B. Brain Tumor Biorepository, Histopathology, and Immunologic Monitoring Core. Roger McLendon, M.D., Core Leader The access to appropriately procured tissue (brain tumor, normal brain, and matched somatic cells) has been fundamental to the success of this NINDS Specialized Research Center on Primary and Metastatic Tumors of the CMS since its inception 25 years ago. This Biorepository has successfully obtained and sorted brain tumor tissue and matched peripheral somatic cells from more than 800 individual brain tumor patients with a net accumulation of more than 6,750 blocks of gliomas tissue. The Duke Immunologic Monitoring component of this Core will provide a variety of standard and in-house developed polychromatic flow cytometric assays of immune function, including intracellular cytokine staining and degranulation within a broad range of phenotypically-defmed T-cell populations on patients in Project 1. The Database component of this Core will store data from the genetic, cytogenetic, immunohistochemical, histologic and diagnostic analyses of all banked brain tumor tissues as well as normal brain samples in the Biorepository and furnish data to researchers requiring these data working in Projects 1, 2, and 3 and the IND, Regulatory, and Bioinformatics Core under Duke IRB oversight. This Core's Specific Aims will support the clinical and preclinical studies described in Projects 1, 2, and 3: 1) Provide and maintain a clinically annotated and catalogued biorepository of human brain tumor tissue, normal human brain tissue, and matched somatic cells from all brain tumor patients in clinical trials in Projects 1, 2, and 3; The Repository has a Nautilus database that will be linked to a clinical Oracle database in which all patients on a clinical trial in Projects 1, 2, and 3 will be entered; 2) Maintain access for scientific questions relative to Projects 1, 2, and 3 for the more than 800 brain tumor patient specimens and their matched somatic ceils entered into this Repository since the inception of this P50 grant in the early 1980s; 3) Provide integrated pathologic, histologic, immunohistochemical, and molecular diagnostic studies for Projects 1, 2, and 3, which will be entered into the Biorepository Nautilus database and linked to the Oracle clinical database for each patient; 4) Provide comprehensive immunologic monitoring of patients enrolled in clinical trials in Projects 1, 2, and 3, using highly standardized/validated state-of-the-art flow cytometry-based assays. RELEVANCE (See instructions): The availability of brain tumor tissue is necessary to determine the eligibility of patients for the clinical trials. Most of the new treatments depend on demonstrating specific molecules in each patient's brain tumor in order to enroll the patient in the appropriate clinical trial. The vaccine studies for malignant gliomas require immunologic monitoring of the responses to the vaccine treatment.